Jeanne Tie
谢珍（戴珍娜）
MBBS, FRACP, PhD
Medical Oncologist; Head, Colorectal Cancer Translational Research Group肿瘤内科医生；结直肠癌转化研究组负责人
👥Biography 个人简介
Jeanne Tie is a world leader in the clinical application of circulating tumor DNA (ctDNA) for detection of minimal residual disease (MRD) and treatment guidance in colorectal cancer. Her landmark studies demonstrated that ctDNA positivity after surgical resection of stage II and III colon cancer strongly predicts relapse and can be used to select patients for adjuvant chemotherapy, work that has fundamentally altered how oncologists approach post-operative surveillance and adjuvant therapy decisions. Her ongoing ctDNA-guided clinical trials are reshaping the adjuvant treatment paradigm in early-stage CRC.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
ctDNA as MRD Biomarker in Stage II Colon Cancer
Published the first prospective clinical study demonstrating that postoperative ctDNA positivity in stage II colon cancer patients identifies those at very high risk of relapse, and piloted ctDNA-guided adjuvant chemotherapy in a randomized setting, establishing ctDNA as the most clinically actionable MRD biomarker in CRC.
ctDNA Dynamics During Adjuvant Chemotherapy
Characterized ctDNA kinetics during and after adjuvant FOLFOX treatment, showing that ctDNA clearance on therapy correlates with improved survival and that ctDNA persistence predicts chemotherapy failure, enabling early adaptive decision-making.
ctDNA in Colorectal Liver Metastases
Conducted prospective studies demonstrating that ctDNA levels after liver metastasectomy predict early recurrence and guide surveillance intensity, supporting the incorporation of liquid biopsy into the postoperative management of CRC liver metastases.
Representative Works 代表性著作
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer
New England Journal of Medicine (2022)
Randomized DYNAMIC trial demonstrating that ctDNA-guided adjuvant treatment decision-making reduced chemotherapy use without compromising recurrence-free survival in stage II colon cancer, establishing ctDNA-guided management as a viable clinical strategy.
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
Annals of Oncology (2015)
Landmark study showing early ctDNA changes predict response and survival in mCRC patients receiving first-line chemotherapy, validating ctDNA as a dynamic treatment response biomarker.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 谢珍（戴珍娜） 的研究动态
Follow Jeanne Tie's research updates
留下邮箱，当我们发布与 Jeanne Tie（Peter MacCallum Cancer Centre, University of Melbourne）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment